Globeflex Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Globeflex Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-16,761	Closed	-$188K	–	561
2016 Q2	$188K	Sell	16,761 -12,639	-43%	-$161K	0.05%	333
2016 Q1	$402K	Hold	29,400	–	–	0.11%	253
2015 Q4	$558K	Buy	29,400 +11,100	+61%	+$241K	0.15%	216
2015 Q3	$343K	Buy	+18,300	New	+$311K	0.07%	324
2014 Q3	–	Sell	-130	Closed	-$1K	–	678
2014 Q2	$1K	Buy	+130	New	+$1.25K	﹤0.01%	538

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Globeflex Capital's CNCE Position: Q3 2016 in Review

Globeflex Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2016, closing a stake of 16,761 shares — an estimated $188K sold.

Globeflex Capital first reported a position in CNCE in Q2 2014 and held it in 5 quarters. The position peaked at $558K in Q4 2015. 94 funds tracked by Wall St. Rank hold CNCE as of Q3 2016.

Globeflex Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Globeflex Capital sold 16,761 Concert Pharmaceuticals, Inc. shares in Q3 2016, an estimated $188K.
Globeflex Capital first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 5 quarters.
Globeflex Capital's Concert Pharmaceuticals, Inc. position peaked at $558K in Q4 2015.
94 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2016.

Based on Globeflex Capital's 13F filing for Q3 2016, filed 9 Nov 2016.